Reorganisation of Commercial Organisation at Solvay Pharma and Fournier Pharma in France
Following its acquisition of Fournier Pharma in July 2005, Solvay Pharmaceuticals has begun a process of reflection in order to integrate the two companies. The aim of this study is to build a "new Solvay Pharmaceuticals" by 2010, an innovative and successful company, able to meet the current and future challenges facing the pharmaceutical industry, through a portfolio of targeted products, a productive and promising R&D pipeline, critical mass and an efficient organisation designed to boost sales and improve profitability.
The strategy of the "new Solvay Pharmaceuticals" will leverage two key therapeutic areas: the neurosciences and cardio-metabolism. The management of the cardiometabolic pole will essentially be operated out of France. In addition, Fournier's research centre based in Dijon will hold an important position in the company's research in these areas, and will be integrated into Solvay Pharmaceuticals' research network.
While honouring the commitment made by Solvay Pharmaceuticals when the acquisition was announced to maintain employment until the end of July 2006, some 400 job cuts are under consideration throughout France in the commercial operations as well as in the support and central functions. Solvay Pharmaceuticals reiterates its intention to hold constructive talks with employee representatives in order to plan and manage the social impact of this integration project in the best possible conditions.
Other news from the department business & finance
